Date/TimeMarch 24, 2022
With the EU Medical Device Regulation (MDR) now fully applicable, manufacturers are facing the challenges of both transitioning legacy devices to the MDR, and introducing new products. Although the Medical Device Coordination Group (MDCG) guidance has been forthcoming, there remain significant gaps in guidance and interpretation of requirements, and varying interpretations of expectations. In addition with the limited number of Notified Bodies designated under the MDR, there is substantial pressure to make MDR submissions as soon as possible to avoid the “cliff edge” of May 2024.
A few examples of the clinical and regulatory challenges include:
- Strategies for Post-Market Clinical Follow-up (PMCF) and implementation of those activities
- New clinical investigation submissions
- Presentation of clinical data within the MDCG and MEDDEV framework.
NAMSA invites you to view this webinar as our team of regulatory experts discuss practical insights to address these challenges.
Attendees can expect to gain a better understanding of:
- Increased clinical data requirements under the EU MDR, particularly in relation to PMCF
- How to define and plan appropriate strategies to meet requirements under the EU MDR
- NAMSA experiences with multiple manufacturers and Notified Bodies
- Challenges faced by other manufacturers and proposed solutions
- Carefully planned MDR submissions
Adrian Keene, BSc (Hons)Director EMEA, Consulting Services
With 26 years of experience in the medical device industry, Adrian’s knowledge of new product development combined with EU regulatory requirements enables him to provide a balanced interpretation of the needs and expectations of both competent authorities and manufacturers. His current responsibilities at NAMSA involve regulatory, quality, biological evaluation and medical writing—working with a broad range of devices including drug-device combination products.
Prior to working at NAMSA, Adrian was Head of Notified Body for the UK Notified Body SGS. Before working with the notified body, he was Global Clinical Affairs and Regulatory Manager for Medical Devices, with responsibility for conformity assessment activities of high risk (class III) devices under the Medical Device Directive (MDD).
Jane Arnold-RoundPrincipal Regulatory Consultant
Jane Arnold-Round has over 25 years of experience in the medical device industry, working with a broad range of medical device technologies and organizations from start-ups to multinationals. She worked as a Notified Body reviewer for over 15 years at BSI as a Medical Device Product Specialist with particular responsibility in the wound-care sector. Prior to joining NAMSA in 2018, she was a Regulatory Consultant for 14 years. Jane’s current focus involves complex submissions for high-risk devices, including development of regulatory and clinical strategies, design dossier and technical file compilations, device-drug consultations, clinical evaluations and regulatory due diligence.
Sara FinocchiettiSenior Clinical Study Manager
Sara Finocchietti serves as Senior Clinical Study Manager at NAMSA, managing both pre- and post-market studies. She has over 10 years’ experience in clinical affairs and management in the medical device industry. She has been working with a wide range of organizations, from start-ups, SMEs and public research entities, bringing innovative products to market or supporting existing portfolios. She was notably Clinical Affairs Manager in a French orthopaedic manufacturer, responsible of the company’s clinical strategy and study management.
Sara has extensive experience of working within cross-functional and cross-cultural teams. She holds a Master Degree in Biomedical Engineering from Italy and a PhD in Clinical Science from Denmark.